RXDX Stock Overview
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD).
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Prometheus Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$113.66 |
| 52 Week High | US$122.75 |
| 52 Week Low | US$21.50 |
| Beta | 0 |
| 1 Month Change | 3.33% |
| 3 Month Change | 128.74% |
| 1 Year Change | 216.43% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 349.43% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03
We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Shareholder Returns
| RXDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -0.2% | 1.7% |
| 1Y | 216.4% | 3.9% | -12.5% |
Return vs Industry: RXDX exceeded the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: RXDX exceeded the US Market which returned -13.6% over the past year.
Price Volatility
| RXDX volatility | |
|---|---|
| RXDX Average Weekly Movement | 48.4% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RXDX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 48% a week.
Volatility Over Time: RXDX's weekly volatility has increased from 25% to 48% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 72 | Mark McKenna | https://www.prometheusbiosciences.com |
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD.
Prometheus Biosciences, Inc. Fundamentals Summary
| RXDX fundamental statistics | |
|---|---|
| Market Cap | US$5.28b |
| Earnings (TTM) | -US$132.91m |
| Revenue (TTM) | US$7.19m |
734.6x
P/S Ratio-39.8x
P/E RatioIs RXDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXDX income statement (TTM) | |
|---|---|
| Revenue | US$7.19m |
| Cost of Revenue | US$106.47m |
| Gross Profit | -US$99.28m |
| Other Expenses | US$33.63m |
| Earnings | -US$132.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.86 |
| Gross Margin | -1,380.19% |
| Net Profit Margin | -1,847.71% |
| Debt/Equity Ratio | 0% |
How did RXDX perform over the long term?
See historical performance and comparison